Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics granted 61,365 RSUs and options to purchase 19,425 shares to eight newly-hired non-executive employees under its 2025 Inducement Equity Plan, effective September 1, 2026. The options have an exercise price of $7.07 per share, with vesting schedules spanning four years for options and multiple years for RSUs, contingent on continued employment.